Please login to the form below

Not currently logged in
Email:
Password:

kidney cancer

This page shows the latest kidney cancer news and features for those working in and with pharma, biotech and healthcare.

Merck bulks up in cancer with $2.2bn Peloton buy

Merck bulks up in cancer with $2.2bn Peloton buy

It is the second pipeline-boosting deal for Merck in three months, coming after it paid $300m for cancer vaccine developer Immune Design. ... VHL is seen in over 90% of cases of clear cell RCC, the most common form of kidney cancer.

Latest news

  • Keytruda monotherapy fails in triple negative breast cancer Keytruda monotherapy fails in triple negative breast cancer

    Metastatic triple-negative breast cancer is an aggressive and challenging disease to treat, especially after progression on initial standard-of-care treatment,” said Dr. ... It added another new indication in April when it gained FDA approval in

  • Merck claims key FDA okay for Bavencio in kidney cancer Merck claims key FDA okay for Bavencio in kidney cancer

    common form of kidney cancer. ... At least kidney cancer is a much larger market with upwards of 70, 000 new cases in the US every year, according to the American Cancer Society.

  • Bad news for BMS as Keytruda kidney cancer combo approved Bad news for BMS as Keytruda kidney cancer combo approved

    Opdivo and Yervoy combination will be squeezed. The FDA has approved Merck’s top-seller Keytruda in combination with Pfizer’s Inlyta for patients with kidney cancer, putting it in direct ... BMS’ lead in kidney cancer was a key area for the company,

  • AVEO warns EU approval of Fotivda could be at risk AVEO warns EU approval of Fotivda could be at risk

    Concerns arose with overall survival data. AVEO Oncology has revealed in a regulatory filing that European Medicines Agency (EMA) approval for its Fotivda kidney cancer drug could be at risk of

  • Keytruda combo outshines Opdivo in kidney cancer Keytruda combo outshines Opdivo in kidney cancer

    Kidney cancer is one of the few therapy areas where BMS has had the upper hand on Merck &Co’s Keytruda, but new data on its use in combination with ... BMS suffered more discouraging news this week when its partner Nektar released updated data on the

More from news
Approximately 23 fully matching, plus 121 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Roche has already chalked up the first successes pairing Tecentriq (atezolizumab) with its veteran anticancer antibody Avastin (bevacizumab) in first-line NSCLC and kidney cancer, with additional trials of the duo ... up innate immune responses, and

  • Pharma deals during April 2014 Pharma deals during April 2014

    Novartis' pipeline includes more than 25 new molecular entities targeting key oncogenic pathways including: Gleevec and its follow-up Tasigna (blood-cancer); Afinitor (kidney cancer and recently approved for breast cancer); ... Additional revenues for

  • Pharma deals during August 2013 Pharma deals during August 2013

    To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic ... This protracted process is indicative of the now

  • Pharma investment in Indonesia Pharma investment in Indonesia

    Under this universal scheme, all healthcare services and drugs for major diseases, such as cancer, chronic kidney disease etc.

  • Interview: David Haslam, NICE Interview: David Haslam, NICE

    NHS Diabetes and Kidney Care and the National Cancer Action Team, have been amalgamated into more wide-reaching bodies that are aiming to reshape the healthcare environment in England. ... UK. Referencing the industry's work in HIV and cancer, Prof

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Mirna hires former Pfizer director as CMO Mirna hires former Pfizer director as CMO

    Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time ... This background will benefit Mirna, which has just

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • A reflection of ESMO

    The objective for this congress is for HCPs to learn from physicians and scientists who present their research in prostate, bladder, and kidney cancer. ... highlighting the ground-breaking research in cancer care.

  • A stumble, but not a fall – what’s next for Opdivo?

    and renal cell carcinoma (kidney cancer). ... Rubbing salt into BMS’s wounds, Merck's  Keytruda snagged a new FDA approval in head-and-neck cancer.

  • Immuno-oncology; bringing patients closer to treatment

    cure; immunotherapies offer positive news for all stakeholders involved in the fight against cancer. ... Immunotherapies can treat head, neck, lung, prostate, renal, multiple myeloma, AML, ALL and kidney cancer.

  • Oncology drugs under AMNOG

    Pfizer’s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines. ... Consistent with EMA market authorisations for other kidney cancer

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics